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Abstract
High-throughput quantiﬁcation of gene expression using microarray technology has
dramatically changed biological investigation into the roles of genes in normal cell
functioning, as well as the mechanisms of disease. We discuss an analytic approach for
framing biological questions in terms of statistical parameters to efﬁciently and conﬁdently
answer questions of interest using microarray data from factorial designed experiments.
Investigators can extract pertinent and interpretable information from the data about the
effects of the factors, their interactions with each other, and the statistical signiﬁcance of these
effects, rather than rely solely on clustering techniques or fold change point estimates in hopes
of ﬁnding co-expressed genes. By ﬁrst examining how biological mechanisms are reﬂected in
mRNA transcript abundance, investigators can better design microarray experiments to
answer the most interesting questions.
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1. Introduction
High-throughput quantiﬁcation of gene expression using microarray technology
has dramatically changed scientiﬁc investigation into the roles of genes in normal cell
functioning, as well as the mechanisms of disease. The challenge to analyze and
interpret large-dimensional microarray output in a variety of experimental settings
calls for unprecedented integration of biological understanding and statistical
methodology. Global expression proﬁling has met with much success for sample type
classiﬁcation and gene function hypothesis generation [1,2,4,8,12,16,21,42,48];
however, the scientiﬁc community lacks biologically interpretable models for the
effects of treatments on speciﬁc genes within the dynamic cellular network for
complex, multifactor experimental designs.
Microarray studies often involve the application of treatments in combination to
model organisms such as cell lines. Cell lines are genetically identical, immortalized
cells which can be grown in culture and manipulated in a tightly controlled manner.
Even though their highly altered state precludes immediate applicability of
experimental results in vivo, cell lines do allow for in depth examination of the
mechanisms involved in cellular response and regulation. Frequently, these studies
are carefully designed factorial experiments meant to pinpoint the perturbation of
genetic networks by various combinations of factors. Practicality and interpretability
often drive investigators to select genes of interest according to multiple pairwise fold
change values without fully exploiting the use of replicates or modeling to assess
statistical signiﬁcance. In this paper, we demonstrate how classic statistical linear
modeling with thoughtful experimental design and biological interpretation of the
parameters offers a natural paradigm for analysis. Interpreting the linear model
parameters to reﬂect the interactivity of genes and their protein products in the cells’
response to treatment affords comprehensive identiﬁcation of genes that respond to
treatment in different ways. This paper also serves as an introduction to the basic
biology that is important for analyzing microarray data from a factorial experiment
on cell lines designed to investigate the details of molecular interactions.
Linear model experimental design principles from the classic agricultural studies
conducted by Fisher [15] have been used to investigate two-color cDNA microarray
data in several different studies, many of which emphasize dye-color and array
assignment for efﬁcient experimental design. An ANOVA model for the log-ratio of
two-color cDNA array data is discussed in a series of papers by Kerr et al. [31–33].
Glonek and Solomon [20] discuss the efﬁciency of experimental designs based on a
new notion of admissibility. Dudoit et al. [11] propose a permutation algorithm for
multiple comparisons adjustment for particular types of designs. Mixed models for
microarray data are considered by Wolﬁnger [54]. A good review of the design issues
for two-color cDNA arrays is given in Yang and Speed [55]. The design element in
these papers pertains more to adjusting or standardizing the arrays for different
experimental conditions and can be thought of as part of the normalization
procedure for two-color arrays. Since we are considering Affymetrix data, the
problems with spot and dye effects for cDNA arrays disappear; however, the results
of these other authors could be incorporated into the linear model if we had cDNA
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data. Dı´az et al. [9] and Jin et al. [29] describe speciﬁc multifactor experiments on
two-color cDNA arrays, and Wayne and McIntyre [52] describe a two-factor
experiment using Affymetrix microarrays for quantitative trait mapping. Our
discussion could be viewed as an extension of these other studies, with a substantial
shift in focus. We demonstrate the importance of multifactor models for
disentangling complex biological experiments and underscore the paramount
importance of carefully coordinating known cellular behavior with statistical
modeling and experimental design in order to make conﬁdent, biologically relevant
inference using microarray data from factorial experiments.
It is well known that, in general, genes do not behave independently of each other
and some parametric models that allow for correlation between genes have been
proposed. For example, Ibrahim et al. [25] describe a Bayesian model for detecting
differentially expressed genes in cancer versus normal tissues with correlation
between genes depending on the number of patients in the normal and tumor
subgroups and two variance parameters in the hierarchical prior structure. The
difﬁculty with parametric models that require a speciﬁed covariance structure for the
observed mRNA transcript levels is that they do not and, given the current state of
scientiﬁc knowledge, cannot accurately reﬂect the biological systems that drive gene
co-regulation. For example, gene expression levels are affected by the activity of
protein complexes [22]. We cannot yet fully characterize the composition of these
complexes, let alone quantify their joint effects on the mRNA transcript levels
[17,24]. The binding of transcription factors to speciﬁc promoter sites also drives the
expression of many genes in a coordinated fashion, but much work remains to be
done to identify transcription factor-promoter relationships. In fact, the gene list
obtained in this analysis is currently being used to identify promoter targets of the
estrogen receptor transcription factor. Once more of these relationships are
identiﬁed, then we can begin to quantify the coregulation of genes in the cell.
While correct multivariate analyses are certainly preferable to univariate analyses,
we proceed with a gene-at-a-time technique to show how candidate genes
demonstrating biologically interpretable expression proﬁles can provide a starting
point from which to understand and possibly construct the regulatory systems in the
cell. Zhao et al. [56] also ﬁnd gene-at-a-time analyses for parametric modeling to be
useful in time-course investigations. Once the genes that result from our selection
criteria are studied in detail, and more knowledge exists about the correct
mechanisms of joint behavior, the univariate linear model can easily be extended
with the appropriate covariance structure to jointly model gene expression, assuming
multivariate Gaussianity holds. Since the response of these genes under certain
treatment conditions is well-summarized by the linear model, the selected genes
would also serve as excellent candidates for the multivariate association determina-
tion model of Kim et al. [34] or the network investigations of Wagner [51] and Ideker
et al. [26].
In Section 2 of this paper, we summarize two basic cellular processes, transcription
and translation, which inform the appropriate analysis and design of microarray
factorial experiments. In Section 3, we describe the objectives of a speciﬁc experiment
on cells from the MCF-7 breast cancer cell line [47] and why the factors were chosen
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to address these objectives. In Section 4, we discuss how mRNA abundance
reﬂects the cellular mechanisms under investigation and state the biological
assumptions necessary for modeling the data. In Section 5, we propose a linear
model for the data from the MCF-7 experiment and explain how the parameters
capture the mRNA abundance patterns noted in Section 4. Section 6 addresses
outlier detection for this particular data set. Section 7 outlines an algorithm for data
analysis according to the statistical model proposed in Section 5. Section 8 presents
the biological results for this analysis. Section 9 proposes extensions of this
methodology to answer other questions in the study and demonstrates a multivariate
model for a small subset of genes. Section 10 addresses some limitations and
advantages of the analysis and design of factorial experiment microarray data using
linear models.
2. Transcription and translation
The nucleus of almost every cell in an organism contains a copy of DNA for that
organism. DNA consists of four nucleotides, adenosine (A), cytosine (C), thymine
(T), and guanine (G), and provides the pattern for manufacturing the functional
components of a cell, namely proteins. The entire DNA sequence, called the genome,
is divided into smaller regions, called genes, which code for speciﬁc proteins based on
their A, C, T, G sequence. Cells behave differently according to their gene expression
pattern; even though cells may have the same genes, different activity levels of these
genes direct the protein composition, and therefore the function, of individual cells.
Genes code for proteins through intermediary nucleotides called mRNA. In a
process called transcription, the nucleotide uracil (U) substitutes for T, and then
(A,U) and (C,G) base-pairing directs the formation of a gene’s complementary
mRNA sequence. In a subsequent process called translation, the mRNA strands
serve as templates for the formation of proteins. The correspondence of DNA to
mRNA to protein explains the relevance of gene expression in characterizing
functional differences in cells. Microarrays measure mRNA rather than protein since
it is easier to work within the lab, and, for most genes, changes in mRNA abundance
are related to changes in protein abundance [38].
DNA is a stable molecule that remains largely unchanged throughout the life of a
cell. mRNA and proteins, on the other hand, are degradable molecules that may
exist only in different types of cells, at different times in a cell’s life, or in response to
external stimuli. Certain proteins called transcription factors control the dynamic
expression of genes seen in varying amounts of mRNA and protein. Treatments in
cell line microarray experiments often target speciﬁc transcription factors to
accomplish desired changes in the cells. Transcription factors bind to a gene’s
promoter sequence that is typically upstream from the actual coding region of the
gene and thereby control mRNA production. Promoter sequences vary among genes
and allow for speciﬁcity of a transcription factor for its target genes. Transcription
factors may increase or decrease the expression of a gene, they may act in
conjunction with other transcription factors, they may bind to similar promoter
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sequences in several genes, and they may compete with other transcription factors
for binding to the same promoter. Furthermore, transcription factors are themselves
proteins which often require regulation by other genes. In such a complex,
interacting system, changing the activity of one transcription factor may change the
expression of its primary (or direct) gene targets, but a number of secondary (or
indirect) effects may also occur.
The living, dynamic system into which treatments enter make factorial
experiments for measuring gene expression in cell lines somewhat different from
classical factorial experiments discussed in statistical literature. While parameter
estimation is procedurally the same, the interpretation of the parameters must
account for multiple directions and magnitudes of the effects, possible interactions of
the treatments, and perhaps most importantly, the interactions of the genes, their
respective protein products, and other cellular components under the treatment
conditions. Simplifying assumptions must be made in order to draw biologically
relevant conclusions from the data, but as in any modeling context, reasonable
assumptions often allow for reasonable conclusions. In Section 4, we discuss the
assumptions that were necessary for the experiment we describe in Section 3, and
demonstrate how our gene selection criteria using linear model contrasts
accomodated interactivity of cellular components and multiple responses to
treatment.
3. The experiment
In this section, we describe in some detail the biology for our particular
experiment of interest. The intention in this section is to demonstrate the design
considerations that must be made when tying the biological details of a factorial
microarray experiment to a statistical linear model. Early collaborations between
biologists and statisticians that frame molecular questions in terms of statistical
parameters can afford more realistic expectations for the types of biological
observations and conclusions allowed by a given experimental design.
The data discussed in this paper come from an experiment on cells from an
estrogen receptor positive (ER+) human breast cancer cell line (MCF-7). There
were four factors in the experiment, each at two different levels: cyclohexamide (CX,
P=present or A=absent), estrogen (ES, speciﬁcally 17b-estradiol, P or A),
treatment Z (Z is an unnamed compound that is still under investigation, P or A),
and length of exposure to treatment (10 or 48 h). Two independent samples of the
MCF-7 cells were exposed to each of the 16 possible combinations of the four
factors, for a total of 32 samples in a 24 factorial design. mRNA transcript
abundance was measured using Affymetrixs HGU95Av2 microarrays. Model-based
expression indices were computed in dChip using the PM-only model after
normalization by the Invariant Set Method [35,36]. All other statistical analyses
were done in R [27] using packages from Bioconductor, including factDesign
(http://www.bioconductor.org).
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The fact that there were only two replicates for each condition does limit the
power to detect statistical signiﬁcance of the treatment effects, particularly the
interactions. The balanced design allowed fairly efﬁcient tests of all combinations of
linear parameters and enabled further analyses of this data beyond the speciﬁc
example discussed in this paper; however, power might have been improved by
considering a fractional factorial design. Possibilities for changing the experimental
design to suit speciﬁc questions of interest will be discussed in Section 9.
One objective of this study was to identify ES target genes, and to further
differentiate between primary and secondary targets (more explicit deﬁnitions will be
made in Section 4). Other questions included the modiﬁcation of ES effects on target
genes by treatment Z through either transcriptional or translational mechanisms, as
well as the consistency of effects over time. We will ﬁrst focus on primary and
secondary estrogen target identiﬁcation at a single time point ð48 hÞ: Although this is
a 24 factorial experiment, we begin as though there are only two factors, CX and ES,
at two levels, P and A. The discussion of this as a 22 factorial experiment simpliﬁes
the considerations in using the experimental design to answer speciﬁc biological
questions. Straightforward extensions incorporate the other factors, some of which
are discussed in Section 9.
ES target identiﬁcation is possible in MCF-7 cells since they are ER+. In breast
cancer cells, ER+ refers to the presence of estrogen receptor (ER) in the cell. When
ES enters the cellular environment, ER binds to ES, and then acts as a transcription
factor for speciﬁc genes. The best understood mechanism of transcriptional control
by ER involves the binding of an ER subtype called ERa to estrogen response
elements (EREs) within the promoter sequence of its target genes [30]. ERa; as well
as the less understood estrogen receptor bðERbÞ; also modulate gene transcription
through other promoters, including AP-1 sites [41]. Since our experimental design
does not allow us to observe individual ES-stimulated pathways, in this paper, we
make no attempt to distinguish between the mechanisms through which the addition
of ES accomplishes changes in gene expression. We simply note the observed
expression levels and look to identify any changes that might be attributable to ES.
Since the MCF-7 cells are ER+, the introduction of ES should at the very least
stimulate transcriptional regulation of the genes with EREs targeted by ERa:
CX is a universal translational inhibitor; that is, it prevents the translation of
mRNA into protein. In cells treated with CX, we can observe the effects of ES and Z,
independent of the production of new protein. Although CX is of tremendous value
in differentiating between primary and secondary ES targets as explained in Section
4, it does complicate matters and is in fact the source of many assumptions made in
the interpretation of the data.
4. Primary and secondary estrogen targets
A primary ES target is a gene that is affected at the mRNA transcript level
when ES is present by a mechanism that does not require the protein products of
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other ES-regulated genes, e.g. a gene with an ERE in its promoter that is directly
recognized by ES-bound ERa: A secondary ES target is a gene that is affected at the
transcript level downstream of an initial ES–gene interaction; that is, a gene whose
expression is induced or suppressed by the protein product of another ES target
gene’s mRNA. The use of CX in this experiment facilitates the distinction between
ES target types.
The biological activity of CX requires several assumptions for interpretation of the
data, mainly related to protein degradation. Protein half-lives are quite variable,
ranging from a few minutes to several days. Once a protein degrades, if CX is
present, new protein cannot be translated to take its place. First, we assume that ER
itself, and any other coregulating proteins that facilitate the activity of ER, do not
degrade so quickly that they are absent in the cell before ES can affect the genes.
Second, we assume that some proteins that exist in the cell at the time of CX addition
do indeed degrade over the course of the experiment, and that this allows for effects
of ES that might not otherwise be observed. We further assume that the proteins
responsible for carrying out the degradation of other proteins do not themselves
degrade to depletion during the experiment. Finally, we assume that many genes are
differentially expressed in the presence of CX simply in response to its drastic effects
on the cell, and therefore take appropriate measures in our analysis to account for
these effects.
Figs. 1–4 propose stylized, hypothetical mechanisms by which ES and CX might
affect mRNA transcript levels of primary and secondary ES targets. These schemes
are highly simpliﬁed; in reality, many more cellular components contribute to the
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Fig. 1. Possible transcription mechanism: condition 1. Primary ES target gene A and secondary ES target
gene B are not active in the untreated samples, nor are they active in the presence of CX alone since
proteins do not regulate their expression. When ES is added alone, gene A produces mRNAA: The
resulting transcription factor TFA induces the transcription of gene B. When CX and ES are both present,
ES-bound ER induces the transcription of gene A, but CX prevents translation of mRNAA into TFA; and
so gene B is not transcribed.
D. Scholtens et al. / Journal of Multivariate Analysis 90 (2004) 19–43 25
ARTICLE IN PRESS
Fig. 2. Possible transcription mechanism: condition 2. TFC induces transcription of primary ES target gene
A, and in turn TFA causes transcription of secondary ES target gene B. When CX is added alone, the
absence of TFC prevents the expression of both genes A and B. When ES is added alone, no difference is
observed in mRNAA or mRNAB since TFC competes with ES-bound ER for binding to gene A’s
promoter. When CX and ES are both present, ES-bound ER now induces the transcription of gene A, but
CX prevents the formation of TFA and gene B is not transcribed.
Fig. 3. Possible transcription mechanism: condition 3. TFC induces transcription of primary ES target gene
A, and its protein product TFA suppresses transcription of secondary ES target gene B. CX inhibits the
production of TFC and TFA; causing moderate abundance of mRNAA and high abundance of mRNAB:
ES added alone suppresses transcription of gene A, and gene B is subsequently transcribed at a moderate
level. When CX and ES are added together, gene A is completely suppressed, and gene B is highly active.
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process through which ES and CX affect the genes. Although these ﬁgures
show joint expression of primary and secondary targets, the goal of this paper
is not to decide which primary and secondary targets act in the same pathway
(however, this is a topic for future research). Rather, these scenarios demonstrate the
mRNA transcript abundance patterns that distinguish between primary and
secondary targets as we might observe them. In all four ﬁgures, gene A (represented
by the solid rectangle labeled A) is the primary ES target and gene B (represented by
the solid rectangle labeled B) is the secondary ES target. mRNA is represented by
rectangles with subscripts matching the corresponding genes; recall that microarrays
measure mRNA transcript abundance so these levels are our observed data.
Transcription factors are represented by ovals with plug-in shapes to match the
indentations in the gene-speciﬁc promoters. TFC is a transcription factor that exists
in the cell at initial exposure to treatment, but degrades fairly quickly, and so by the
time of data collection is absent in the presence of CX. Transcription is represented
by a single arrow with the number of ‘+’ or ‘’ signs representing the strength of
expression induction or suppression. CX is a lightning bolt and ER is a tulip shape.
ES is a pie-shape that ﬁts into ER. ER will only bind to the promoter of primary
target gene A in the presence of ES. Table 1 summarizes the observed mRNA levels
in Figs. 1–4.
Consider Fig. 1. Genes A and B are both inactive in the untreated cell. The
addition of CX alone does not change the (in)activity of these genes since a
transcription factor does not regulate their expression. Exposure to ES alone enables
ER to induce expression of gene A, whose protein product TFA then induces
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Fig. 4. Possible transcription mechanism: condition 4. Genes A and B are moderately expressed in the
presence of TFC and TFA: CX prevents the production of both transcription factors, so neither gene is
transcribed. ES alone enhances transcription of gene A, and in turn gene B is highly expressed. CX and ES
added together results in moderate transcription of gene A, but the lack of new protein production due to
CX prevents transcription of gene B.
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expression of gene B. When both CX and ES are present, gene A produces mRNAA
as expected, but translational inhibition by CX prevents expression of gene B.
In Fig. 2, ES-bound ER and TFC compete for binding to the promoter for gene A.
When there is no treatment, TFC induces expression of gene A, and in turn, TFA
induces expression of gene B. In the presence of CX alone, TFC is no longer
available, so production of mRNA transcripts for both genes A and B stops. When
ES is added alone, there is no change in the mRNAA transcript level since TFC
already causes gene A to express as much mRNAA as possible. When ES and CX are
added together, TFC is absent, but gene A is still expressed in response to the
presence of ES. mRNAB is not present, however, due to the lack of TFA:
In Fig. 3, gene A is transcribed in response to TFC; and produces TFA which
suppresses gene B. In the presence of CX alone, neither TFC nor TFA are present,
allowing only moderate expression of gene A and high expression of gene B. When
ES is added alone, the effect of TFC is dampened, causing lower expression of gene
A. There is then less TFA; so only moderate abundance of mRNAB: When both CX
and ES are present, ES completely suppresses gene A, and gene B expresses at a high
level in the absence of TFA:
Finally, consider Fig. 4. TFC induces transcription of gene A, and TFA induces
transcription of gene B. In the presence of CX, both genes are not expressed due to
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Table 1
Observed mRNA transcript abundance in Figs. 1–4
Treatment mRNAA mRNAB
Fig. 1
None Low Low
CX Low Low
ES High High
CX,ES High Low
Fig. 2
None High High
CX Low Low
ES High High
CX,ES High Low
Fig. 3
None High Low
CX Moderate High
ES Moderate Moderate
CX,ES Low High
Fig. 4
None Moderate Moderate
CX Low Low
ES High High
CX,ES Moderate Low
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the lack of the transcription factors that stimulate their expression. The addition of
ES causes gene A to be expressed more than when TFC is present alone, causing
higher levels of both mRNAA and TFA; and, in turn, higher levels of mRNAB: When
both CX and ES are present, gene A is still expressed due to the presence of ES, but
again at a moderate level since TFC is now absent. Gene B is no longer expressed due
to the absence of TFA:
Figs. 1–4 represent a few highly simpliﬁed mechanisms by which ES might alter
the expression of its gene targets. There are certainly many more possibilities, but
these four examples demonstrate two patterns that distinguish between primary and
secondary targets of ES. (1) For primary targets, ES will change the gene’s mRNA
transcript level in some way, whether or not CX is present. (2) For secondary targets,
the mRNA transcript level that is observed when both CX and ES are present should
be the same as the transcript level when CX is present alone. ES may have an effect
when introduced alone, but CX should prevent any alteration in the expression of a
secondary target gene caused by new protein synthesis.
Note that the use of CX as a factor in this experiment allows for convenient
interpretations of the observable data in regards to primary and secondary
transcriptional regulation by ES. Since microarrays measure mRNA transcript
abundance, CX was particularly useful given the nature of the technology and the
observable data for the genes of interest. This is an example of the type of
conclusions that are possible by designing experiments with carefully selected factors
under reasonable assumptions about the behavior of those factors. Other factors
would provide similarly valuable information for other questions of interest. In
Section 9, we consider extensions of the modeling framework to other questions in
this particular study.
Given the variety of ways in which mRNA transcript levels of both primary and
secondary targets change in the presence of ES, the challenge in this experimental
setting is to develop efﬁcient, comprehensive gene selection criteria that encompass
the different combinations of effect size and direction. The statistical model
presented in Section 5 aims to do just that.
5. Statistical model
In this section, we discuss the interpretation of the parameters in the linear model
for the factorial designed estrogen target experiment. As stated in the Introduction,
well-informed multivariate models would certainly be desirable for assessing the
activity of genes in concert with other genes when exposed to various levels of
treatment, but the current state of biological knowledge does not afford such
sophisticated and realistic characterization of genetic interactivity. We adopt a gene-
at-a-time univariate analysis of the treatment effects for the high-throughput
identiﬁcation of primary and secondary estrogen targets. Once the common
biological regulators of the estrogen targets are better understood, then appropriate
joint models can be formulated.
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Consider the data for a single time point and exposure to the two levels (P and A)
of ES and CX for a total of eight samples in a 22 factorial design. Suppose log ygi; the
log of the observed expression level ygi of gene gðg ¼ 1;y; nÞ in chip iði ¼ 1;y; 8Þ
after proper normalization, can be modeled as in (1) where egiBNð0; s2Þ and xCXi
and xESi are indicator variables for the presence of CX and ES in sample i
respectively:
logðygiÞ ¼ mg þ bgCXxCXi þ bgESxESi þ bgCX:ESxCXixESi þ egi: ð1Þ
The bg coefﬁcients represent gene-speciﬁc main effects for CX and ES and their two-
way interaction; in what follows, the g subscripts are dropped, but the estimated
parameters are still assumed to be gene-speciﬁc. Estimation of the coefﬁcients using
least squares is straightforward, and under the assumption of Normality, p-values
for these estimates easily follow. A log transformation helps satisfy the assumption
of Normality in our data set. Model checking will be addressed in Section 6. While
the actual model ﬁtting and parameter estimation applies straightforward linear
model theory, the interpretation of the parameters in this speciﬁc biological
framework is the challenge.
For the purpose of ES target identiﬁcation, the estimates of m and bCX are not
particularly informative. m describes the mRNA level in the cell without the addition
of the factors, and bCX measures the effect on the gene of preventing new protein
synthesis. The parameters bES and bCX:ES describe the effects of ES on the gene in the
presence and/or absence of CX. As we saw in Section 4, ES may not affect the
mRNA transcript level unless CX is also present. The interaction term bCX:ES is
therefore just as important as bES for determining target status, and so both bES and
bCX:ES direct the selection of ES targets. We can test the null hypothesis H0ESt (2)
using nested linear models, and if we reject H0ESt; conclude that the gene is affected
by ES at the transcriptional level and is therefore an ES target.
H0ESt : bES ¼ bCX:ES ¼ 0 ð2Þ
Since this hypothesis test is performed individually on thousands of genes, multiple
comparisons is an obvious issue. Recent literature, including Dudoit et al. [10] and
Reiner et al. [45], suggest that control of the false discovery rate (FDR) is more
appropriate for microarray data than other procedures that control the family wise
error rate (FWER). We use the FDR method for general dependence structures of
the hypothesis tests under consideration proposed by Benjamini and Yekutieli [3].
This method is known to be somewhat conservative, so in this analysis, we used a p-
value cutoff of 0.10 which permitted the identiﬁcation of several known ES targets.
In our case, a rejected hypothesis indicates an ES target, so we can interpret the FDR
as the proportion of falsely identiﬁed ES targets. Permutation tests that reasonably
accomodate the structure in this data are of interest and are currently under
investigation.
Once ES targets are identiﬁed, the next step is to differentiate between primary
and secondary ES targets. Consider the mRNA transcript abundance pattern for
primary target gene A in Fig. 1. When ES is added alone, we observe an increase in
mRNAA; indicating that bES40: When ES is added in the presence of CX, we see the
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same increase in mRNAA; so bCX:ES ¼ 0: bES40 and bCX:ES ¼ 0 correspond to
Condition 1 in Table 2. There is a similar correspondence between the mRNAA
levels in Figs. 2–4 and Conditions 2–4. Note that Conditions 5–8 in Table 2 are
simply directional opposites of Conditions 1–4. These eight combinations for the
values of bES and bCX:ES summarize all of the different ways in which we can observe
expression alteration by ES in presence of CX as we should for primary targets. In
fact, these eight conditions can be summarized as bES þ bCX:ESa0: This can be seen
by considering all (in)equality possibilities of the parameters bES and bCX:ES in
relation to 0 ðo;4;¼Þ:
Now consider the mRNA transcript abundance pattern for secondary target gene
B in Fig. 1. When ES is introduced alone, we observe an increase in mRNAB;
indicating that bES40: When ES is added in the presence of CX, the amount of
mRNAB is the same as when CX was added alone, indicating that bCX:ESo0 and in
fact bES þ bCX:ES ¼ 0: In all Figs. 1–4, bCX:ES in some sense ‘‘reverses’’ bES so that
the observed mRNAB levels are the same in the presence of CX, regardless of the
addition of ES. This is consistent with the biology of secondary targets in that ES
should not have an effect if translation cannot occur.
The fact that bES þ bCX:ESa0 for primary targets and bES þ bCX:ES ¼ 0 for
secondary targets provides concise criteria for differentiating between the two.
Speciﬁcally, for the ES targets that are selected according to H0ESt (2), we can test the
linear contrast
H0pt : bES þ bCX:ES ¼ 0 ð3Þ
and if we reject H0pt (3), conclude that the gene is a primary ES target. Otherwise, it
is a secondary ES target. When power is low, we run the risk of falsely identifying
primary ES targets as secondary ES targets. Techniques that allow for primary,
secondary, and ‘‘undecided’’ ES target distinctions are currently being examined.
Selecting ES targets and differentiating between primary and secondary ES targets
is completely reliant upon the data we can observe in this experiment. Note the
secondary ES target gene B in Fig. 2. For this gene, bCXo0; but bES ¼ bCX:ES ¼ 0:
We would fail to select this gene as an ES target at all, let alone identify it as a
secondary ES target. This is a limitation of this particular experimental design in that
the downstream effect of ES for this gene cannot be observed. There may well be
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Table 2
Parameter combinations for primary ES targets
Condition no. bES bCX:ES Condition no. bES bCX:ES
1 40 ¼ 0 5 o0 ¼ 0
2 ¼ 0 40 6 ¼ 0 o0
3 o0 o0 7 40 40
4a 40 o0 8a o0 40
a jbESjajbCX:ESj:
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similar situations in this experiment; other studies with different experimental
designs might prove useful in improving upon the list of ES target genes.
An added feature of the linear contrast selection technique in (3) for primary
targets is its relationship to fold change criteria that is often used to select induced or
suppressed genes. Consider the ratio of the mRNA level for a gene for cells treated
with ES and CX to those treated with CX alone. For log-transformed data, the fold
change null hypothesis H0fc for differential expression would be
H0fc :
expðmþ bCX þ bES þ bCX:ESÞ
expðmþ bCXÞ
¼ expðbES þ bCX:ESÞ ¼ 1: ð4Þ
A gene for which H0fc (4) is rejected might be considered a primary ES target since
any change in expression in the presence of both ES and CX, when compared to CX
alone, signiﬁes expression alteration directly due to ES. Algebraically, the equation
in H0fc (4) can be reduced to the contrast criteria proposed in H0pt (3). More
restrictive criteria for fold change magnitude can be imposed by changing H0fc (4) to
reﬂect the fold change induction or suppression of interest.
6. Outlier detection
The replicate structure of the experiment under consideration allows for a
specialized algorithm for outlier detection. Studentized residuals from the regression
model are generally used for model checking in the linear model framework;
however, in a small factorial design, the usual residuals have a large number of linear
dependencies relative to the number of residuals. We focus on the set of differences
between the replicates since these differences naturally inherit the independence and
Normality that we assume for the original observations. If we had more observations
at each treatment condition, then it could be better to use the usual studentized
residual approach for model checking.
For each individual gene, consider the squared differences between r sets of
replicate observations, say d21 ;y; d
2
r ; where d
2
i ¼ ðlogðyi1Þ  logðyi2ÞÞ2 for all i ¼
1;y; r: If logðyi1Þ and logðyi2Þ are Normally distributed with variance s2i =2 for all
i ¼ 1;y; r; then the d2i =s2i are w21 random variables. Under a null hypothesis of
constant variance s2i =2 ¼ s2=2 for all i ¼ 1;y; r;
f ¼
d2ðrÞ
1
r  1
Pr1
i¼1 d
2
ðiÞ
ð5Þ
is F1;r1 where d2ðiÞ is the ith order statistic (i ¼ 1;y; r). An adjusted p-value to test
for suspected outliers can be calculated by r  PfFð1; r  1Þ4f g; the adjustment
taken since f compares the maximum squared difference of replicate observations to
the mean of the rest. When fXr  1; this adjusted p-value is exact, otherwise it is an
upper bound for the true p-value.
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Since this statistic evaluates differences between observations, it only identiﬁes
which pair the outlier observation may come from, not the outlier observation itself.
For some genes, such as those in Fig. 5a, the outlier observation is easily identiﬁed.
In other cases, such as the observations in Fig. 5b and c, pairs with large differences
between the replicates are identiﬁed, but it is inappropriate to label one observation
as an outlier rather than the other. For this reason, once pairs with signiﬁcantly large
differences are identiﬁed, a second criteria is applied to exclude questionable cases
from being labeled as single outliers. In particular, if only one of the tagged replicates
falls outside the range of ðmede  4 made;mede þ 4 madeÞ where mede is the
median of the expression values for the gene and made is the median absolute
deviation of the expression values for the gene, the observation is designated the
single outlier.
In our analysis, we discarded 49 data points as single outliers and parameter
estimates were computed based on the remaining observations. Other outlier
detection methods, such as those discussed in Carey et al. [5], could also be
employed. While robust regression techniques may be of interest, we note, as do
Yang and Speed [55], that robust estimation techniques for small sample sizes
require further development for microarray data.
7. Selection algorithm
Our algorithm for primary and secondary ES target selection is outlined below.
The algorithm can be suitably adjusted for other experiments.
(1) Average the replicate observations and exclude any genes with a maximum
average less than 100. (For Affymetrix data, PM-only expression indices from
dChip that are less than 100 are taken to indicate genes that are not expressed.)
This step limits our investigation to genes with reliabily detected expression
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Fig. 5. Examples of primary targets. TFF1 (trefoil factor 1 (breast cancer, estrogen-inducible sequence
expressed in)), ERBB2 (HER2/NEU), and CYP1B1 (cytochrome P450, subfamily I (dioxin-inducible),
polypeptide 1 (glaucoma 3, primary infantile)) were identiﬁed as primary targets in our analysis. In all
three examples, ES affects transcript levels in the presence of CX, indicating that these genes are primary
ES targets.
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under at least one of the experimental conditions. Remove all Affymetrix control
sequences.
(2) Apply any necessary transformations to satisfy normality, and then test
for single outliers as in Section 6. If outliers are detected, remove them from
the data set.
(3) Fit the linear model proposed in Eq. (1) for each gene.
(4) Test H0ESt : bES ¼ bCX:ES ¼ 0 (2) for each gene.
(5) Reject H0ESt (2) for the genes with Benjamini and Yekutieli [3] FDR-adjusted p-
values less than 0.10. Call these genes ES targets.
(6) For the ES targets, test H0pt : bES þ bCX:ES ¼ 0 (3). Call all ES target genes with
p-valueso0:01 for the test of H0pt (3) primary ES targets. Call the remaining ES
target genes secondary ES targets. As discussed in Section 5, this may result in
the false identiﬁcation of primary ES targets as secondary ES targets. Enhanced
categorization methods are under investigation.
8. Results
The results presented here are from an analysis of the 16 observations in the 48 h
experiment. We adjusted step 3 in the algorithm in Section 7 and ﬁt a linear model
for the log-transformed expression values with main effects for CX, ES, and Z, and
all possible two-way interactions. In principle, the smaller 22 factorial experiment
can be analyzed, but in practice there are substantial beneﬁts in terms of power to
including more observations.
For our application, Step 1 in the gene selection algorithm reduced the number of
genes under investigation from 12 625 to 12 352. Step 2 detected 49 single outliers.
Step 5 selected 305 ES target genes. Step 6 identiﬁed 130 of these as primary ES
targets, and 175 as secondary ES targets. The speciﬁc primary and secondary target
genes are reported at http://www.bioconductor.org/Docs/Papers/2002/FactorialDe-
sign. The Bioconductor package factDesign contains functions useful for selecting
genes according to the algorithm in Section 7. After identifying contrasts of
biological interest, investigators can easily proceed with the hypothesis testing. A
function for the outlier detection technique described in Section 6 is also available in
this package.
The observations for three genes that we identiﬁed as primary targets are recorded
in Fig. 6. The contrast test p-value for H0pt (3) is included in these plots (contrast p),
as is the nominal p-value for the bES parameter estimate (ES p). In these plots,
observations on the left (right) of the dotted line are for samples that were unexposed
(exposed) to CX. All samples exposed to Z are white circles. Gray (black) circles are
for samples unexposed (exposed) to ES. TFF1 (trefoil factor 1, pS2) and ERBB2
(HER2=NEU), respectively, exhibit increased and decreased expression in the
presence of ES, regardless of the presence of CX. mRNA transcript abundance for
CYP1B1 (cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma
3, primary infantile)) increases in the presence of ES only when CX is also present.
These three plots demonstrate the variety of direction and magnitude of expression
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differences that our selection criteria detect. The comparison of the observed
expression levels in the presence of CX to those in the presence of CX and ES suggest
that ES affects transcription of these genes without requiring intermediate proteins
thus satisfying the deﬁnition of primary ES target in Section 3.
Fig. 7 demonstrates the mRNA levels for three genes we identiﬁed as secondary
targets. The expression of BRCA1 (breast cancer 1, early onset) is increased in the
presence of ES alone, but when ES is added in the presence of CX, the expression
level remains the same as when CX is added alone. ES triggers a decrease in the
expression of GADD45A (growth arrest and DNA-damage-inducible alpha) and
JUN (v-jun sarcoma virus 17 oncogene homolog (avian)), but this same decrease
does not transpire in the presence of CX. All three plots demonstrate patterns of
secondary ES targets in that ES alters their expression level, but in the presence of
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Fig. 6. Examples of secondary targets. BRCA1 (breast cancer 1, early onset), GADD45A (growth arrest
and DNA-damage-inducible, alpha), and JUN (v-jun sarcoma virus 17 oncogene homolog (avian)) were
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CX, expression levels do not change. We ascribe this to the inhibition of translation,
though there could be other reasons.
8.1. Comparison with genes reported in literature
There are several primary ES target genes described in the literature, and in
general, our methodology selects these genes as primary targets. TFF1 (trefoil factor
1, pS2) [40], CCND1 (cyclin D1, PRAD1) [43], CTSD (cathepsin D) [53], and
CYP1B1 (cytochrome P450, subfamily 1, (dioxin-inducible) polypeptide 1 (glaucoma
3, primary infantile)) [23] are all well-characterized, long-standing primary ES
targets. ERBB2 (HER2=NEU) is a breast cancer diagnostic marker whose expression
is inhibited by direct transcriptional repression by ES [7]. An experiment involving
CX demonstrated that GREB1 (KIAA0575 gene product) is directly controlled by
ES-bound ER [18]. Similarly, CX does not prevent an increase in mRNA levels for
TRIM16 (EBBP; tripartite motif-containing 16) [37] due to ES-bound ER. We
identify all of these documented primary ES targets.
Some reported primary ES targets are not contained in our list, for example
NRIP1 (nuclear receptor interacting protein 1) [6]. NRIP1 was not identiﬁed due to
the multiple comparisons adjustment using FDR; however, when the contrast test
H0pt (3) is applied to the observations for NRIP1; the p-value is less than 0.01. This
omission demonstrates the familiar difﬁculty with multiple comparisons adjustment
and p-value cutoffs in that some positive results are not identiﬁed. LIV-1 (LIV-1)
protein, estrogen regulated) is another direct ES target [13] that we did not identify.
In our data set, the observations for LIV-1 were too variable for distinction as an ES
target.
Our secondary target list is also conﬁrmed by recent literature and suggests that
there is great potential for network construction using the ES target genes we report.
BRCA1 is a known secondary ES target [39] that is, among other things, a
transcription factor for many genes including GADD45A (growth arrest and DNA-
damage-inducible, alpha) [14]. BARD1 (BRCA1 associated RING domain 1) and
RBBP8 (retinoblastoma binding protein 8, CtIP) co-regulate transcriptional control
by BRCA1 [28,49]. All four of these genes are reported on our secondary target list.
JUN and FOS are known to participate with ERa in transcriptional control at
AP1 promoter sites [50]. DDIT3 (DNA-damage-inducible transcript 3, GADD153) is
known to be transcriptionally regulated, at least in part, by AP1 transcription factors
[44]. These three genes are reported on our secondary target list.
9. Extensions
9.1. Other biological questions
The methodology discussed for the two factors CX and ES can easily be extended
to questions requiring information from the other factors. Consider a linear model
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including all four main effects for CX, ES, Z, and TIME and possible interactions
for log ygi; the log of observed expression level ygi of gene gðg ¼ 1;y; nÞ in chip
iði ¼ 1;y; 32Þ; with error term egiBNð0; s2Þ:
Suppose we want to ﬁnd genes that behave like primary ES targets at the
transcriptional level at 10 and/or 48 h. Biologically speaking, this requires
differential expression of genes in the presence of CX compared to the presence of
CX and ES at one or both time points. In terms of statistical parameters, either
statement (6) or (7) should be true:
mþ bCXamþ bCX þ bES þ bCX:ES; ð6Þ
mþ bCX þ bTIME þ bCX:TIMEa mþ bCX þ bES þ bTIME
bCX:ES þ bCX:TIME þ bES:TIME þ bCX:ES:TIME: ð7Þ
If the null hypothesis for the simultaneous set of contrasts in (8) is rejected,
H0 :
bES þ bCX:ES ¼ 0;
ðbES þ bES:TIMEÞ þ ðbCX:ES þ bCX:ES:TIMEÞ ¼ 0;

ð8Þ
then either (6) or (7) are true, and the gene behaves as a primary ES target for at least
one time point.
In addition to primary and secondary target selection, the biologists involved in
this experiment were interested in modiﬁcation of the effect of ES by Z. For
simplicity, consider only one time point. In this case, the genes of interest should
exhibit differential expression in the presence of Z and ES when compared to ES
alone. That is, the statement in (9) should be true:
mþ bESamþ bES þ bZ þ bES:Z: ð9Þ
If the null hypothesis H0 : bZ þ bES:Z ¼ 0 is rejected, then there is either a change in
the expression of the gene directly due to a main effect of Z or the combination of the
main effect and the ES:Z interaction. In either case, the expression of these genes in
the presence of ES is altered by Z.
In addition to assessing overall modiﬁcation of ES effects by Z, the biological
investigators were further interested to identify which genes, in the presence of ES,
are regulated by Z through transcriptional control rather than translational control.
Since CX is a translational inhibitor, the expression levels in the presence of CX and
ES should be different from those when CX, ES, and Z are all present. In this case,
the statement in (10) should be true:
mþ bCX þ bES þ bCX:ESa mþ bCX þ bES þ bZ
þ bCX:ES þ bCX:Z þ bES:Z þ bCX:ES:Z: ð10Þ
Rejecting the null hypothesis H0 : ðbZ þ bCX:ZÞ þ ðbES:Z þ bCX:ES:ZÞ ¼ 0 would
identify genes that are affected by Z in the presence of ES through posited
direct transcriptional control. The behavior of Z in the presence of ES and CX at
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both time points could be investigated by coordinating all four factors in the
experiment.
The balanced 24 factorial design of this experiment allowed any comparison of
main effects and interactions to be tested with reasonably high efﬁciency, thereby
facilitating investigation into all the biological questions that were just described. If
the experiment was more limited in scope, then allocating the 32 samples to different
treatment conditions could have increased the power. If the only question of interest
in the study had been the identiﬁcation of genes with modiﬁcation of ES by Z
through transcriptional control, i.e. testing H0 : ðbZ þ bCX:ZÞ þ ðbES:Z þ bCX:ES:ZÞ ¼
0; then we could have exposed half of the samples to CX and ES and half of the
samples to CX, ES and Z for the most efﬁcient design. In our case, such a design
would have been impractical due to the multiplicity of questions under considera-
tion, and the replicated 24 design allowed for all hypotheses of interest to be tested in
an efﬁcient manner.
In this paper, we have only considered data collected on Affymetrix arrays as part
of a single experiment. For comparative two-color cDNA arrays, we could extend
the linear model of Kerr et al. [31–33] as follows in (11):
logðyijklgÞ ¼ mþ Ai þ Dj þ V1k þ V2l þ Gg þ ðV1V2Þkl þ ðAGÞig
þ ðV1GÞkg þ ðV2GÞlg þ ðV1V2GÞklg; ð11Þ
where logðyijklgÞ is the log red–green ratio of gene expression for the ith array, jth
dye, kth level of variety 1 ðV1Þ; lth level of variety 2 ðV2Þ; and gth gene, Ai represents
the effects of the ith array, Dj represents the effect of the jth dye, V1k represents the
effect of the kth level of V1; V2l represents the effect of the lth level of V2; Gg
represents the effect of the gth gene, ðV1V2Þkl represents the interaction between the
kth level if V1 and the lth level of V2; ðAGÞig represents the interaction of array i and
gene g; and ðV1GÞkg; ðV2GÞlg; and ðV1V2GÞklg represent the interactions between the
kth level of V1; the lth level of V2; and gene g: The last three variety-gene interaction
terms correspond directly to the terms in our linear model (1), and would be used for
gene selection using the technique we have outlined. The limma, daMA, and
factDesign packages in Bioconductor would be helpful in such an analysis.
Consideration could be given to extending a linear model to combine data from
different experiments and technologies, but the parameterization would be much
more difﬁcult.
9.2. Multivariate models
As stated in the Introduction, genes that are known to be coregulated could
be analyzed using a multivariate model, rather than separate univariate
models. For demonstration, we used the data from TFF1 (HGU95av2 probe
31798 atÞ; ERBB2 ð33218 atÞ; CCND1 ð38418 atÞ; CYP1B1 ð859 atÞ; and CTSD
ð239 atÞ; all of which are literature-reported primary ES targets, and tested H0pt (3)
using a multivariate normal model with two different structures for the covariance
matrix on the genes. ERBB2; CCND1; and CYP1B1 all have multiple probes on the
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Affymetrix HGU95av2 chips; we used the probe sets speciﬁed above because they
gave consistent expression estimates within replicates.
Fig. 8 illustrates the correlation estimates from the multivariate normal model
with an unstructured covariance matrix. Care must be taken in interpreting these
estimates. These correlations represent relationships between genes in the departure
of their observed data from the predicted values estimated by the model, and should
not be confused with an overall correlation in the expression proﬁle of the genes
under the various experimental conditions. For example, in Fig. 8, a negative
correlation is reported for TFF1 and CTSD; but the expression of both of these
genes increases in the presence of ES both in our experiment and in several others
[19,46].
In addition to the unstructured covariance matrix, we also analyzed the same ﬁve
genes using a heteregeneous compound symmetry structure for the covariance
matrix. The AIC criteria, 42:0 for the unstructured case and 28:9 for the
heterogeneous compound symmetry case, suggest that the simpler covariance
structure does not provide a good ﬁt to the data. While the biological interpretability
of the estimated correlation matrix remains to be shown, the estimate, for these ﬁve
known primary ES-target genes, suggests that a simple correlation structure is
inadequate for these data.
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Fig. 8. Primary ES target multivariate model, unstructured covariance matrix. The direction and magnitude
of the correlation resulting from the covariance matrix estimate in the multivariate normal model for
TFF1; ERBB2; CCND1; CYP1B1; and CTSD is indicated by the slant and width of the ellipse,
respectively, with a narrower ellipse indicating stronger correlation.
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10. Discussion
This paper demonstrates the careful coordination of experimental design and
biological function of the factors in a microarray study for the identiﬁcation of
primary and secondary ES targets. No less important was the coordinated efforts of
biologists and statisticians in making sense of the resultant data. Incorporating
universal translational inhibition by CX and the transcription factor behavior of ER
upon binding to ES into the interpretation of the model enabled the identiﬁcation of
genes of interest using standard statistical linear modeling. Multiple comparisons
adjustment according to FDR provided a natural data reduction step and helped
quantify the proportion of falsely identiﬁed genes. Statistical signiﬁcance according
to the p-values for the tests of H0ESt (2) and H0pt (3) provide a measure of conﬁdence
in the genes that were selected as ES targets.
The use of CX in this experiment facilitated convenient interpretations for
the parameters in the statistical model under the assumption of universal
translational inhibition in the presence of CX. Since microarrays are designed to
measure mRNA transcript abundance, and given our interest in transcriptional
regulation by ES, this was a particularly useful factor for addressing the main
objective of this study. Factors with such dramatic effects in the cell are not
necessary in these types of experiments. Section 9 in this paper addressed the use of
several contrast tests to investigate alteration of expression by Z. Factors with
smaller effects can provide just as interpretable results depending on the research
question of interest.
Often times, the goal of a microarray experiment is to identify genes that might
compose a functional pathway or network in the cell with the aim to explore these
genes individually using gene-at-a-time experiments. Wagner [51] discusses the
reconstruction of genetic networks using various gene perturbations including point
mutations, gene deletions, over-expression, or inhibition of translation, and then
proposes a graph-theoretic framework for inferring direct effects of these
manipulations. Gene selection according to statistical parameters from carefully
designed microarray studies, such as the one described here, would provide much
better candidates for these types of experiments than large-scale clustering or
ﬁltering analyses. The known interactions between several of the genes on our
primary and secondary list underscore the great promise for future research in
constructing genetic networks using these types of experiments that may inform the
more desirable multivariate models of gene behavior.
The limitations in this methodology are the same as those in any setting involving
multiple comparisons or linear models. We used the Benjamini and Yekutieli [3]
FDR method for general dependence structures based on current research into
multiple comparisons adjustment for microarray data [10,11,45]. Regarding the
linear model, as in any factorial experiment, the higher-order interaction terms are
somewhat difﬁcult to interpret individually. Under appropriate assumptions about
the biology, the mechanisms that we suspect drive the observations of mRNA
transcript abundance do somewhat alleviate this problem. Unless the experimental
design is quite simple and existing permutation tests can be used, we must also make
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the familiar normality assumption for computing statistical signiﬁcance for all of the
parameters in the linear model. The development of permutation models that
accomodate the experimental design and the testing of all required interactions will
alleviate the need for this assumption.
Despite the limitations, the use of experimental design in the analysis of
microarray data can be used to efﬁciently and conﬁdently address speciﬁc questions
about cellular function that are reﬂected in mRNA transcript abundance. Once the
connection between the observed data and the statistical parameters is understood,
there is tremendous ﬂexibility in selecting genes that demonstrate biological
behaviors of interest. The design of microarray experiments with this type of
analysis in mind will greatly enhance the characterization of gene behavior.
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